Evidence map›Paper›PMID 41253767›Full record

ArticleNature communications2025

Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy.

Zhijun Liu, Ravindra Joshi, Zhongguo Zhou, Fulin Liu, Ying Gong, Mingyan Sun, Xiuxiu Li, Tao Jiang, Liang Zou, Siyuan Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhijun LiuDepartment of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China.
Ravindra JoshiDepartment of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-0077-1513
Zhongguo ZhouDepartment of Surgery & Cancer, Faculty of Medicine, Imperial College London, London, UK.
Fulin LiuSichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.ORCID http://orcid.org/0000-0002-0072-0847
Ying GongDepartment of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China.
Mingyan SunDepartment of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China.
Xiuxiu LiDepartment of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China.
Tao JiangDepartment of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China.
Liang ZouSchool of Food and Biological Engineering, Chengdu University, Chengdu, China.
Siyuan WangUrology (Department), Sichuan Clinical Research Center for Cancer, Sichuan. Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Yi ShiSichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. shiyi1614@126.com.
Zong-Hong LinDepartment of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. zhlin@ntu.edu.tw.ORCID http://orcid.org/0000-0002-1793-7858
Yang-Bao MiaoDepartment of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China. miaoyangbao@uestc.edu.cn.ORCID http://orcid.org/0000-0001-7705-8567

Funding

Department of Science and Technology of Sichuan Province (Sichuan Provincial Department of Science and Technology) 2024ZHYS0018National Natural Science Foundation of China (National Science Foundation of China) 32401173National Natural Science Foundation of China (National Science Foundation of China) 82271120
6 · The paper itself

Abstract

Bladder cancer ranks among the most prevalent malignancies affecting the urinary system worldwide. Despite advances in treatment, poor drug penetration and uncontrolled release continue to impede the effectiveness of chemotherapy for this disease. To overcome these obstacles, we have developed a self-driven electrical triggering system, which leverages intravesical pressure to produce electricity. This electronic trigger system can rapidly transport hydroxycamptothecin through tunneling nanotubes, acting as a high-speed channel, thereby enhancing the drug absorption by tumor cells. Additionally, the voltage generated by this system effectively induces reactive oxygen species (ROS), further promoting the eradication of bladder cancer cells. In orthotopic female animal models of bladder cancer, our results indicate that an intravesical pressure-driven system in the bladder generates electricity to facilitate drug release and rapid diffusion through a tunneling nanotube highway, while also effectively generating ROS to eliminate bladder cancer cells. This self-driven electrical trigger system, coupled with a tunneling nanotube highway to transport drugs, offers renewed hope for bladder cancer treatment. With its potential to transform current therapeutic approaches, this system is poised for deeper exploration in research and clinical settings.

Indexed as

CamptothecinDrug Delivery SystemsNanotubesUrinary Bladder NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorDrug LiberationFemaleHumansMiceReactive Oxygen SpeciesUrinary BladderXenograft Model Antitumor AssaysAntineoplastic AgentsCamptothecinReactive Oxygen Species

Identifiers

PMID41253767
PMCPMC12627709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.